November 18, 2025 — Leads & Copy — Quanterix Corporation has announced the publication of a study in the journal Brain, validating the use of multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) in monitoring Multiple Sclerosis (MS) disease activity and progression.
The study, led by Professor Jens Kuhle from the University Hospital Basel and University of Basel, confirms that GFAP and NfL serum biomarkers offer insights into the MS disease course. Elevated serum GFAP levels were associated with an increased risk of Progression Independent of Relapse Activity (PIRA), which is a slow, progressive deterioration often difficult to detect. Serum NfL’s role as a predictor of future relapses and monitor of acute disease activity was also confirmed.
The combination of GFAP and NfL monitoring allows clinicians to gain a clearer understanding of a patient’s condition and progression risk. Extensive Simoa-based normative reference databases for both GFAP and NfL were utilized to translate test results into clinical action. An online tool is available for clinicians to interpret patient results using age, sex, and BMI to assess biomarker status and progression risk.
Professor Kuhle stated that the long-term course of MS involves lesion activity and neurodegenerative processes, and serum GFAP addresses the need for a biomarker that reflects and predicts chronic progression independent of acute activity. Masoud Toloue, CEO at Quanterix, added that the integration of GFAP and NfL solidifies a new avenue for improving personalized therapy for MS patients, and the company’s platform delivers sensitive assays in a multiplexed test.
The study, “GFAP and NfL as Predictors of Disease Progression and Relapse Activity in Fingolimod Treated Multiple Sclerosis,” utilized the automated HD-X instrument and the 2-plex kit that measures NfL and GFAP simultaneously (Simoa Neurology 2-Plex B). Observations indicated that GFAP levels decreased under fingolimod treatment, suggesting a potential mechanism of action for this drug class.
Quanterix is a global company that focuses on ultra-sensitive biomarker detection to enable advancements in disease research, diagnostics, and drug development. Their Simoa® technology delivers sensitivity for detecting biomarkers in blood and other fluids. The company acquired Akoya Biosciences in 2025, adding multiplexed tissue imaging with single-cell resolution.
Contact:
Investor Relations
[email protected]
Source: Quanterix
